Meeting
2019 Gastrointestinal Cancers Symposium
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
Authors
Yung-Jue Bang
Seoul National University Hospital, Seoul, Korea, Republic of (South)
Yung-Jue Bang , Bella Kaufman , Ravit Geva , Salomon M. Stemmer , Sook-Hee Hong , Jong-Seok Lee , Susan M. Domchek , Mark C. Lanasa , Mei Tang , Christopher Gresty , Helen K Angell , Laura L.M. Opincar , Pia Maarit Herbolsheimer , T.R. Jeffry Evans
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02734004
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 140)
DOI
10.1200/JCO.2019.37.4_suppl.140
Abstract #
140
Poster Bd #
L12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.
First Author: Tae-Yong Kim
Poster
2021 ASCO Annual Meeting
Biomarker-oriented study of durvalumab in combination with olaparib and paclitaxel in gastric cancer: A phase 2 trial-in-progress.
First Author: Tae Yong Kim
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma.
First Author: Erica S. Tsang
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok